Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma
Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma
复制标题
DOI：
10.1158/1078-0432.ccr-06-1315
复制
发表时间：
2006-11-01
影响因子：
11.5
通讯作者：
Tanigawa, Nobuhiko
中科院分区：
文献类型：
--
作者：
Fujita, Yoshihisa;Nakanishi, Toyofumi;Tanigawa, Nobuhiko
目的：新的肿瘤相关抗原和自身抗体的检测将有助于早期癌症的诊断和更有效的免疫疗法的开发。本研究的目的是使用基于蛋白质组学的方法鉴定食管鳞状细胞癌（ESCC）细胞系（TE-2）中的新型肿瘤抗原和ESCC患者血清中的相关自身抗体。通过二维PAGE分离TE-2蛋白，然后进行Western印迹分析，其中ESCC患者，健康对照，并对其他癌症患者进行了一级抗体检测。从银染凝胶上切下阳性斑点，并通过基质辅助激光解吸/电离飞行时间质谱法进行分析（MALDI-TOF/TOF MS）。来自ESCC患者的血清产生多个斑点，经MALDI-TOF/TOF MS鉴定，其中一个为过氧化物氧还蛋白（Prx）VI。ESCC患者和30例健康人中的2例（6.6%）。在30例其他类型的癌症（结肠癌）患者中，有1例（3.3%）血清中发现了抗PrxVI自身抗体。结论：我们首次在ESCC患者中发现了抗PrxVI自身抗体。蛋白质组学方法在这里实施提供了一个强大的工具，用于识别新的血清标志物，可能显示临床实用性对癌症。
Purpose: Detection of novel tumor-related antigens and autoantibodies will aid in diagnosis of early-stage cancer and in development of more effective immunotherapies. The purpose of this study was to identify novel tumor antigens in an esophageal squamous cell carcinoma (ESCC) cell line (TE-2) and related autoantibodies in sera from patients with ESCC using a proteomics-based approach.Experimental Design: TE-2 proteins were separated by two-dimensional PAGE, followed by Western blot analysis in which sera of patients with ESCC, healthy controls, and patients with other cancers were tested for primary antibodies. Positive spots were excised from silver-stained gels and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/TOF MS).Results: Sera from patients with ESCC yielded multiple spots, one of which was identified as peroxiredoxin (Prx) VI by MALDI-TOF/TOF MS. Western blot analysis against recombinant Prx A showed reactivity in sera from 15 of 30 (50%) patients with ESCC and 2 of 30 (6.6%) healthy individuals. Autoantibody against PrxVI was found in sera from 1 of 30 (3.3%) patients with other types of cancer (colon cancer).Conclusion: We have identified for the first time an autoantibody against PrxVI in ESCC patients. The proteomic approach implemented here offers a powerful tool for identifying novel serum markers that may display clinical usefulness against cancer.